View:
PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(3)
to Prospectus dated August 2, 2000 Registration No. 333-36318
$200,000,000
INCYTE GENOMICS, INC.
5.5% CONVERTIBLE SUBORDINATED NOTES DUE 2007
and
SHARES OF COMMON STOCK
ISSUABLE UPON CONVERSION OF THE NOTES
This prospectus supplement relates to the resale by the holders of 5.5%
convertible subordinated notes due 2007 of Incyte Genomics, Inc. and the shares
of common stock issuable upon conversion of the notes.
This prospectus supplement should be read in conjunction with the
prospectus dated August 2, 2000, which is to be delivered with this prospectus
supplement.
The information in the table appearing under the heading "Selling
Securityholders" in the prospectus is supplemented and superseded in part by
the information appearing in the table below:
Principal Amount Common Stock
of Notes Common Stock Owned After
Beneficially Issuable Upon Completion
Owned and Conversion Common Stock of the
Name Offered(1) of the Notes(1) Offered(1) Offering(1)
---- ---------------- --------------- ------------ ------------
Argent Classic Convertible Arbitrage Fund
(Bermuda) L.P............................ $8,000,000 59,330 59,330 -
Deutsche Bank Securities Inc.................. $10,073,000 74,703 74,703 -
McMahan Securities Co. L.P.................... $500,000 3,708 3,708 -
Morgan Stanley & Co............................ $10,000,000 74,162 74,162 -
------------
(1) Amounts indicated may be in excess of the total amount registered due
to sales or transactions exempt from the registration requirements of
the Securities Act of 1933 since the date on which selling
securityholders provided information to us regarding their notes.
None of the selling securityholders listed above nor any of their
affiliates, officers, directors or principal equity holders has held
any position or office or has had any material relationship with us
within the past three years.
--------------------
Investing in the notes and our common stock involves a high degree of
risk. You should carefully read and consider the "Risk Factors" beginning on
page 3 of the prospectus.
--------------------
Neither the Securities and Exchange Commission nor any state securities
commission has approved or disapproved of these securities or passed upon the
accuracy or adequacy of this prospectus supplement or the prospectus. Any
representation to the contrary is a criminal offense.
--------------------
The date of this Prospectus Supplement is August 18, 2000.